BioFusionNet: Deep Learning-Based Survival Risk Stratification in ER+ Breast Cancer Through Multifeature and Multimodal Data Fusion

Raktim Kumar Mondol,Ewan K.A. Millar,Arcot Sowmya,Erik Meijering
2024-06-03
Abstract:Breast cancer is a significant health concern affecting millions of women worldwide. Accurate survival risk stratification plays a crucial role in guiding personalised treatment decisions and improving patient outcomes. Here we present BioFusionNet, a deep learning framework that fuses image-derived features with genetic and clinical data to obtain a holistic profile and achieve survival risk stratification of ER+ breast cancer patients. We employ multiple self-supervised feature extractors (DINO and MoCoV3) pretrained on histopathological patches to capture detailed image features. These features are then fused by a variational autoencoder and fed to a self-attention network generating patient-level features. A co-dual-cross-attention mechanism combines the histopathological features with genetic data, enabling the model to capture the interplay between them. Additionally, clinical data is incorporated using a feed-forward network, further enhancing predictive performance and achieving comprehensive multimodal feature integration. Furthermore, we introduce a weighted Cox loss function, specifically designed to handle imbalanced survival data, which is a common challenge. Our model achieves a mean concordance index of 0.77 and a time-dependent area under the curve of 0.84, outperforming state-of-the-art methods. It predicts risk (high versus low) with prognostic significance for overall survival in univariate analysis (HR=2.99, 95% CI: 1.88--4.78, p<0.005), and maintains independent significance in multivariate analysis incorporating standard clinicopathological variables (HR=2.91, 95\% CI: 1.80--4.68, p<0.005).
Computer Vision and Pattern Recognition,Artificial Intelligence
What problem does this paper attempt to address?
The paper aims to address the issue of survival risk stratification for estrogen receptor-positive (ER+) breast cancer patients, to guide personalized treatment decisions and improve patient outcomes. Specifically, the study proposes a deep learning framework named BioFusionNet, which integrates multiple features from histopathological images, genomic data, and clinical information to achieve this goal. The main contributions of BioFusionNet include: 1. **Multimodal Survival Risk Prediction Model**: This model integrates histopathological images, genomic features, and clinical data to provide a more comprehensive assessment of the survival risk for ER+ breast cancer patients. 2. **Weighted Cox Loss Function**: To handle the imbalance in survival data, the paper proposes a specially designed weighted Cox loss function to improve prediction accuracy. 3. **Interpretability Analysis**: It offers an in-depth analysis of how different genes and clinical factors influence risk prediction, aiding in the understanding of the predictive mechanisms behind the model. The development of this model takes into account the complexity and heterogeneity of breast cancer, particularly in ER+ breast cancer, which includes the Luminal A and Luminal B subtypes. These subtypes differ in biological behavior, necessitating more precise risk assessment tools to guide treatment strategy selection. By combining multiple data types, BioFusionNet can better capture the complex interactions between cellular, molecular, and clinical factors, thereby enhancing prediction accuracy. In summary, the goal of this study is to develop a new multimodal survival risk prediction model to more accurately predict the survival risk of ER+ breast cancer patients and support personalized treatment decisions.